3-rx.comCustomer Support3-rx.com
Find a product
    HomeAbout UsFAQContactHelp
 
   
 
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics
Online Pharmacy



Tacrolimus ( ta-KROE-li-mus) ointment is used for moderate to severe atopic dermatitis. This is a skin condition where there is itching, redness and inflammation, much like an allergic reaction


Join our Mailing List

Men`s Health sites at Top100biz.com




Syndicate

You are here : 3-RX.com > Home > Breast Cancer -

Breast cancer prevention practices vary across Canada

Breast CancerAug 14, 07

Breast cancer preventive practices for Canadian women carrying the cancer gene vary across the country, says University of Toronto research, and many women are not taking advantage of the options available.

The study, published in the journal Open Medicine, followed the experiences of Canadian women with a BRCA1 or BRCA2 mutation – a genetic mutation that predisposes them to a 87 per cent lifetime risk of developing Breast cancer. Women carrying the gene have several options for cancer prevention including prophylactic surgery, chemoprevention and screening; however, researchers observed significant differences across Canada in the uptake of these preventions, with women in Quebec the least likely to use preventive measures. 

“We were very surprised by the discrepancy in preventative measures taken across the country,” says Professor Kelly Metcalfe, Lawrence Bloomberg Faculty of Nursing, lead author of the study. “The benefit of genetic testing is that we can identify women at high risk of developing Breast cancer and hopefully reduce that risk. Ultimately though, women have to elect to undertake one of the options.”

In the study, 672 Canadian women were identified as carrying the genetic mutation. Followup questionnaires were completed after a mean of four years. Out of the 342 women without Breast cancer after four years, 157 (46 per cent) had not undertaken any cancer prevention option such as a mastectomy, oophorectomy or tamoxifen or raloxifene – drugs used in chemoprevention. Broken down geographically, 39 per cent of women with the genetic mutation in Ontario did not take preventive measures; 34 per cent in Western Canada and 62 per cent in Quebec.

“The numbers show a huge discrepancy, with women in Quebec being the least likely to elect for a preventive option,” Metcalfe says. “This will have significant implications in terms of the numbers of cancers we see developing in this high-risk group. We still need to do more research to explain why these differences exist.”
###

CONTACT:

Professor Kelly Metcalfe
Lawrence Bloomberg Faculty of Nursing
416-978-2851
Kelly.metcalfe@utoronto.ca

Karen Kelly
Strategic Communications
416-978-5949
k.kelly@utoronto.ca



Print Version
Tell-a-Friend

RELATED ARTICLES:
  New statistical model could help reduce breast-lesion biopsies
  Tamoxifen easier on the brain than thought: study
  Latinas more likely to regret breast cancer treatment decisions
  Scientists unravel breast cancer drug resistance
  How women can improve their quality of life after breast cancer treatment
  Review examines breast cancer prevention strategies in the United States
  Breast cancer awareness month spotlights oral mucositis: Side effect of anticancer therapy
  Common gene determines if breast is best
  Bone fracture ups risk of male breast cancer
  Most women satisfied with cosmetic breast surgery
  ‘Fantastic 4’ of breast procedures leave women extremely satisfied
  Poor mood persists for breast cancer patients

 


Advertisement
















Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site